Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
71,661,062
Share change
+18,262,835
Total reported value
$1,590,188,145
Put/Call ratio
125%
Price per share
$22.19
Number of holders
148
Value change
+$426,293,719
Number of buys
115
Number of sells
34

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q4 2022

As of 31 Dec 2022, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 148 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 71,661,062 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, RTW INVESTMENTS, LP, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., FMR LLC, COWEN AND COMPANY, LLC, STATE STREET CORP, VANGUARD GROUP INC, Avidity Partners Management LP, and Cormorant Asset Management, LP. This page lists 148 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.